CIP2A
CIP2A (cellular inhibitor of PP2A) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.
Overview
Acts as an inhibitor of protein phosphatase PP2A. Promotes anchorage-independent cell growth and tumour formation by preventing dephosphorylation of MYC, thereby stabilising MYC in human malignancies. Together with TOPBP1, plays an essential role in the response to genome instability generated by the presence of acentric chromosome fragments derived from shattered chromosomes within micronuclei.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Gemcitabine.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CIP2A (cellular inhibitor of PP2A) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.
- 1 · What it is
CIP2A (cellular inhibitor of PP2A) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.
- 2 · What goes wrong in cancer
Acts as an inhibitor of protein phosphatase PP2A. Promotes anchorage-independent cell growth and tumour formation by preventing dephosphorylation of MYC, thereby stabilising MYC in human malignancies.
- 3 · How drugs use it
No product in this corpus aims at CIP2A yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:29302 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q8TCG1 (protein name, function text, keywords and locations (REST API)); CIViC gene CIP2A (2 evidence items, 0 assertions, 2 variants; diseases: Pancreatic Ductal Adenocarcinoma (GraphQL API, CC0))
Biology
Acts as an inhibitor of protein phosphatase PP2A. Promotes anchorage-independent cell growth and tumour formation by preventing dephosphorylation of MYC, thereby stabilising MYC in human malignancies. Together with TOPBP1, plays an essential role in the response to genome instability generated by the presence of acentric chromosome fragments derived from shattered chromosomes within micronuclei. Micronuclei, which are frequently found in cancer cells, consist of chromatin surrounded by their own nuclear membrane: following breakdown of the micronuclear envelope, a process associated with chromothripsis, the CIP2A-TOPBP1 complex tethers chromosome fragments during mitosis to ensure clustered segregation of the fragments to a single daughter cell nucleus, facilitating re-ligation with limited chromosome scattering and loss. Location: Cytoplasm; Chromosome (UniProt). Locus 3q13.13 (HGNC).
- Pancreatic ductal adenocarcinoma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 2 clinical evidence items on its variants; UniProt keyword "DNA damage". Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CIP2A" OR ABSTRACT:"CIP2A" OR TITLE:"cellular inhibitor of PP2A" OR ABSTRACT:"cellular inhibitor of PP2A" OR TITLE:"KIAA1524" OR ABSTRACT:"KIAA1524") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CIP2A, not a curated reading list.